JP2016518820A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016518820A5 JP2016518820A5 JP2016502169A JP2016502169A JP2016518820A5 JP 2016518820 A5 JP2016518820 A5 JP 2016518820A5 JP 2016502169 A JP2016502169 A JP 2016502169A JP 2016502169 A JP2016502169 A JP 2016502169A JP 2016518820 A5 JP2016518820 A5 JP 2016518820A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- item
- 16mer
- lna
- items
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims description 79
- 238000000034 method Methods 0.000 claims description 37
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 13
- 108091028684 Mir-145 Proteins 0.000 claims description 10
- 125000001921 locked nucleotide group Chemical group 0.000 claims description 7
- 230000000295 complement effect Effects 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 3
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 3
- 208000037812 secondary pulmonary hypertension Diseases 0.000 claims description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 3
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims description 2
- 208000020875 Idiopathic pulmonary arterial hypertension Diseases 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 13
- 241000124008 Mammalia Species 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 210000002064 heart cell Anatomy 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000008263 liquid aerosol Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000005265 lung cell Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 230000008692 neointimal formation Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 101150066718 FMOD gene Proteins 0.000 description 1
- 101150034559 IGF1R gene Proteins 0.000 description 1
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 1
- 101150103418 MEGF6 gene Proteins 0.000 description 1
- 101100338252 Mus musculus H2aw gene Proteins 0.000 description 1
- 208000034827 Neointima Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 101150048506 Rapgef2 gene Proteins 0.000 description 1
- -1 Sec1412 Proteins 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361800755P | 2013-03-15 | 2013-03-15 | |
| US61/800,755 | 2013-03-15 | ||
| PCT/US2014/026538 WO2014151835A1 (en) | 2013-03-15 | 2014-03-13 | Locked nucleic acid inhibitor of mir-145 and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016518820A JP2016518820A (ja) | 2016-06-30 |
| JP2016518820A5 true JP2016518820A5 (enExample) | 2017-04-06 |
| JP6410791B2 JP6410791B2 (ja) | 2018-10-24 |
Family
ID=51581048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502169A Expired - Fee Related JP6410791B2 (ja) | 2013-03-15 | 2014-03-13 | Ｍｉｒ−１４５のロックト核酸阻害剤およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9752143B2 (enExample) |
| EP (1) | EP2968396B1 (enExample) |
| JP (1) | JP6410791B2 (enExample) |
| CN (1) | CN105188715B (enExample) |
| CA (1) | CA2902623A1 (enExample) |
| WO (1) | WO2014151835A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11241296B2 (en) | 2005-11-17 | 2022-02-08 | Breast-Med, Inc. | Imaging fiducial markers and methods |
| WO2017184751A1 (en) * | 2016-04-20 | 2017-10-26 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treating and preventing hypertension |
| JP6842779B2 (ja) * | 2016-10-31 | 2021-03-17 | 国立大学法人岐阜大学 | 二本鎖核酸分子、およびその用途 |
| US20240301407A1 (en) * | 2021-01-18 | 2024-09-12 | Regen Innopharm Inc. | Composition comprising mir 145 inhibitor as active ingredient for treatment of myocardial infarction |
| CN122180770A (zh) * | 2023-07-06 | 2026-06-09 | 帝国理工学院创新有限公司 | Rna分子 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995003843A1 (en) | 1993-07-30 | 1995-02-09 | The Regents Of The University Of California | Endocardial infusion catheter |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US7803782B2 (en) | 2003-05-28 | 2010-09-28 | Roche Madison Inc. | Intravenous delivery of polynucleotides to cells in mammalian limb |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6416510B1 (en) | 1997-03-13 | 2002-07-09 | Biocardia, Inc. | Drug delivery catheters that attach to tissue and methods for their use |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US6749617B1 (en) | 1997-11-04 | 2004-06-15 | Scimed Life Systems, Inc. | Catheter and implants for the delivery of therapeutic agents to tissues |
| US6833361B2 (en) | 1998-05-26 | 2004-12-21 | Ribapharm, Inc. | Nucleosides having bicyclic sugar moiety |
| SK17432000A3 (sk) | 1998-05-26 | 2001-07-10 | Icn Pharmaceuticals, Inc. | Zlúčenina, ktorá zahŕňa nukleozid s 2',4'-mostíkom a oligonukleotid z nej odvodený |
| DE60045706D1 (de) | 1999-03-18 | 2011-04-21 | Exiqon As | Detektion von genmutationen mittels lna primer |
| EP1334109B1 (en) | 2000-10-04 | 2006-05-10 | Santaris Pharma A/S | Improved synthesis of purine locked nucleic acid analogues |
| US20050124566A1 (en) | 2001-05-18 | 2005-06-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA) |
| EP2428570B1 (en) | 2001-09-28 | 2018-05-23 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Microrna molecules |
| US7781415B2 (en) | 2003-02-07 | 2010-08-24 | Roche Madison Inc. | Process for delivering sirna to cardiac muscle tissue |
| KR20050115231A (ko) | 2003-02-10 | 2005-12-07 | 내셔날 인스티튜트 오브 어드밴스드 인더스트리얼 사이언스 앤드 테크놀로지 | 포유동물 세포의 조절 |
| WO2005013901A2 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| US20070203445A1 (en) | 2004-02-26 | 2007-08-30 | V-Kardia Pty Ltd | Isolating cardiac circulation |
| US7722596B2 (en) | 2004-02-26 | 2010-05-25 | Osprey Medical, Inc. | Regional cardiac tissue treatment |
| CA2557480A1 (en) | 2004-02-26 | 2005-09-09 | V-Kardia Pty Ltd | Isolating cardiac circulation |
| ES2534300T3 (es) | 2004-11-12 | 2015-04-21 | Asuragen, Inc. | Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| WO2006089340A2 (en) | 2005-02-23 | 2006-08-31 | V-Kardia Pty Ltd | Polynucleotide delivery to cardiac tissue |
| US8592384B2 (en) | 2005-04-04 | 2013-11-26 | The Board Of Regents Of The University Of Texas System | Micro-RNA's that regulate muscle cells |
| WO2006113540A2 (en) | 2005-04-14 | 2006-10-26 | Duke University | Use of ntrosylated hemoglobin |
| CA2634046A1 (en) | 2005-12-12 | 2007-06-21 | The University Of North Carolina At Chapel Hill | Micrornas that regulate muscle cell proliferation and differentiation |
| CA3042781C (en) * | 2006-04-03 | 2021-10-19 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| EP2011891A1 (en) | 2006-04-21 | 2009-01-07 | JFE Steel Corporation | Brake disc having high temper softening resistance |
| DK2056882T3 (da) | 2006-08-01 | 2012-11-19 | Univ Texas | Identifikation af en mikro-rna, som aktiverer ekspression af en tung kæde med beta-myosin |
| DK2205737T3 (da) * | 2007-10-04 | 2013-05-21 | Santaris Pharma As | Mikromirer |
| EP2279267A4 (en) | 2008-03-27 | 2012-01-18 | Vascular Biosciences Inc | METHOD FOR IDENTIFYING NEW THERAPY CANDIDATES ON GENE EXPRESSION ANALYSIS IN DISEASES RELATED TO VACCINES |
| US8735568B2 (en) | 2009-03-09 | 2014-05-27 | The J. David Gladstone Institutes | Methods of modulating smooth muscle cell proliferation and differentiation |
| DK2427472T3 (en) | 2009-05-05 | 2016-09-12 | Miragen Therapeutics | Lipophilic polynukleotidkonjugater |
| MA33488B1 (fr) | 2009-06-08 | 2012-08-01 | Miragen Therapeutics | Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn |
| CN102382824A (zh) | 2010-09-01 | 2012-03-21 | 中国科学院上海药物研究所 | 人miR-145反义核酸及其应用 |
| EP2652151A2 (en) * | 2010-12-15 | 2013-10-23 | Miragen Therapeutics | Microrna inhibitors comprising locked nucleotides |
| WO2012153135A1 (en) * | 2011-05-09 | 2012-11-15 | University Of Glasgow | Methods of modulating micrornas in the treatment of pulmonary arterial hypertension |
| EP2864482A4 (en) * | 2012-06-21 | 2016-02-10 | Miragen Therapeutics Inc | OLIGONUCLEOTIDE INHIBITORS COMPRISING A BLOCKED NUCLEIC ACID PATTERN |
-
2014
- 2014-03-13 CA CA2902623A patent/CA2902623A1/en not_active Abandoned
- 2014-03-13 CN CN201480015816.XA patent/CN105188715B/zh not_active Expired - Fee Related
- 2014-03-13 EP EP14768310.6A patent/EP2968396B1/en not_active Not-in-force
- 2014-03-13 JP JP2016502169A patent/JP6410791B2/ja not_active Expired - Fee Related
- 2014-03-13 US US14/777,172 patent/US9752143B2/en not_active Expired - Fee Related
- 2014-03-13 WO PCT/US2014/026538 patent/WO2014151835A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108136206B (zh) | 抗乙型肝炎病毒的组合物和药剂及其用途 | |
| JP5991922B2 (ja) | アンチセンス抗ウイルス性化合物およびインフルエンザウイルス感染を処置するための方法 | |
| EP3128008B1 (en) | Double-stranded oligo rna and pharmaceutical composition comprising same for preventing or treating fibrosis or respiratory diseases | |
| JP2015525081A5 (enExample) | ||
| JP2017519766A5 (enExample) | ||
| JP2007527240A5 (enExample) | ||
| JP2017527294A5 (enExample) | ||
| JP2016522674A5 (enExample) | ||
| TW201406774A (zh) | 微ｒｎａ之ｍｉｒ－１５家族之抑制劑 | |
| JP7318166B2 (ja) | マイクロｒｎａ２２の阻害剤 | |
| EP2948551B1 (en) | Composition comprising an encapsulated antagomir | |
| JP2019524151A5 (enExample) | ||
| CN108350456A (zh) | 治疗性寡核苷酸 | |
| TW202342747A (zh) | 具有高穩定性和基因沉默活性的小干擾rna分子的修飾模式 | |
| JP2011515357A5 (enExample) | ||
| JP6410791B2 (ja) | Ｍｉｒ−１４５のロックト核酸阻害剤およびその使用 | |
| KR20150064065A (ko) | 엠피레귤린 특이적 이중 나선 올리고 rna, 그러한 이중나선 올리고 rna 를 포함하는 이중나선 올리고 rna 구조체 및 이를 포함하는 호흡기 질환의 예방 또는 치료용 조성물 | |
| KR101783444B1 (ko) | miR-33-5p 를 이용한 뇌신경세포 보호 물질 스크리닝 방법 | |
| KR102110103B1 (ko) | 암의 예방 또는 치료용 약학적 조성물 | |
| EP4185694B1 (en) | Combinatorial inhibition of mirnas for treatment of heart failure | |
| JP2024529930A (ja) | 低減されたオフターゲット効果を有する修飾低分子干渉ｒｎａ分子 | |
| JP7692829B2 (ja) | Ｍｕｒｆ１を標的とする核酸医薬 | |
| US20240327830A1 (en) | Dise-inducing srna-polyplexes and srna-lipopolyplexes and methods of using the same to treat cancer | |
| CN104630223B (zh) | 包含POKEMON基因的siRNA的运输载体颗粒及其制备方法 | |
| JP2024057599A (ja) | マイクロｒｎａ２２の阻害剤 |